179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development

179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development

Bibliographic Details
Main Authors: Razelle Kurzrock, Shumei Kato, Jacob Adashek, Alexey Goloubev
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-a34ea7c603134541b3d2712eeaed2768
record_format Article
spelling doaj-a34ea7c603134541b3d2712eeaed27682020-12-11T10:00:40ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0179179 Immunotherapy trials lack a biomarker for inclusion: implications for drug developmentRazelle Kurzrock0Shumei Kato1Jacob Adashek2Alexey Goloubev3Aff4 0000 0001 2107 4242grid.266100.3Center for Personalized Cancer Therapy and Clinical Trials Office, Division of Hematology and Oncology, Clinical Science, Department of MedicineUniversity of California San Diego Moores Cancer Center 3855 Health Sciences Drive 92093 La Jolla CA USA Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA1University of South Florida, Moffitt Cancer Center, Tampa, FL, USA2Morsani College of Medicine, USF, Tampa, FL, USA
collection DOAJ
language English
format Article
sources DOAJ
author Razelle Kurzrock
Shumei Kato
Jacob Adashek
Alexey Goloubev
spellingShingle Razelle Kurzrock
Shumei Kato
Jacob Adashek
Alexey Goloubev
179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
Journal for ImmunoTherapy of Cancer
author_facet Razelle Kurzrock
Shumei Kato
Jacob Adashek
Alexey Goloubev
author_sort Razelle Kurzrock
title 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
title_short 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
title_full 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
title_fullStr 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
title_full_unstemmed 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
title_sort 179 immunotherapy trials lack a biomarker for inclusion: implications for drug development
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT razellekurzrock 179immunotherapytrialslackabiomarkerforinclusionimplicationsfordrugdevelopment
AT shumeikato 179immunotherapytrialslackabiomarkerforinclusionimplicationsfordrugdevelopment
AT jacobadashek 179immunotherapytrialslackabiomarkerforinclusionimplicationsfordrugdevelopment
AT alexeygoloubev 179immunotherapytrialslackabiomarkerforinclusionimplicationsfordrugdevelopment
_version_ 1724386698506272768

Similar Items